1
|
Lecuru F, Sehouli J, Vergote I, Reuss A, Classe JM, Hillemanns P, Greggi S, Mirza M, Brachet P, Follana P, Raban N, Hasenburg A, Zang R, Lindemann K, Kim JW, Poveda A, Raspagliesi F, Haslund C, du Bois A, Harter P. 573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Lindemann K, Škof E, Colombo N, González-Martín A, Davidson R, Blakeley C, Bennett J, Barnicle A, Poveda A. 740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Colombo N, Gadducci A, Sehouli J, Biagioli E, Nyvang GB, Riniker S, Montes A, Ottevanger N, Zeimet A, Vergote I, Funari G, Baldoni A, Tognon G, De Censi A, Galaz CC, Chekerov R, Maenpaa J, Rulli E, Fossati R, Poveda A. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2260] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
4
|
Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger P, Hanker L, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A. Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. Gynecol Oncol 2019; 152:235-242. [DOI: 10.1016/j.ygyno.2018.11.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 10/30/2018] [Accepted: 11/06/2018] [Indexed: 10/27/2022]
|
5
|
Pasquali S, Colombo C, Bottelli S, Verderio P, Broto J, Lopez--Pousa A, Ferrari S, Poveda A, Quagliolo V, Gronchi A. The sarculator predicted risk of distant metastasis and overall survival in patients with high-risk soft tissue sarcoma treated with perioperative chemotherapy in a randomised controlled trial. Eur J Surg Oncol 2018. [DOI: 10.1016/j.ejso.2018.07.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
Friedlander M, Rau J, Lee C, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King M, Debruyne P, Bologna A, Malander S, Monk B, Petru E, Calvert P, Herzog T, Barrett C, du Bois A. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy. Ann Oncol 2018; 29:737-743. [DOI: 10.1093/annonc/mdx796] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Poveda A, Del Campo JM, Ray-Coquard I, Alexandre J, Provansal M, Guerra Alía EM, Casado A, Gonzalez-Martin A, Fernández C, Rodriguez I, Soto A, Kahatt C, Fernández Teruel C, Galmarini CM, Pérez de la Haza A, Bohan P, Berton-Rigaud D. Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Ann Oncol 2018; 28:1280-1287. [PMID: 28368437 PMCID: PMC5452066 DOI: 10.1093/annonc/mdx111] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial ovarian cancer. Patients and methods Patients with platinum-resistant/refractory ovarian cancer were included in a two-stage, controlled, randomized (in a second stage), multicenter, phase II study. Primary endpoint was overall response rate (ORR) by RECIST and/or GCIG criteria. The exploratory first stage (n = 22) confirmed the activity of PM01183 as a single agent at 7.0 mg flat dose every 3 weeks (q3wk). The second stage (n = 59) was randomized and controlled with topotecan on days 1-5 q3wk or weekly (every 4 weeks, q4wk). Results ORR was 23% (95% CI, 13%-37%) for 52 PM01183-treated patients. Median duration of response was 4.6 months (95% CI, 2.5-6.9 months), and 23% (95% CI, 0%-51%) of responses lasted 6 months or more. Ten of the 12 confirmed responses were reported for 33 patients with platinum-resistant disease [ORR = 30% (95% CI, 16%-49%)]; for the 29 patients treated with topotecan in the second stage, no responses were found. Median PFS for all PM01183-treated patients was 4.0 months (95% CI, 2.7-5.6 months), and 5.0 months (95% CI, 2.7-6.9 months) for patients with platinum-resistant disease. Grade 3/4 neutropenia in 85% of patients; febrile neutropenia in 21% and fatigue (grade 3 in 35%) were the principal safety findings for PM01183. Conclusion PM01183 is an active drug in platinum-resistant/refractory ovarian cancer and warrants further development. The highest activity was observed in platinum-resistant disease. Its safety profile indicates the dose should be adjusted to body surface area (mg/m2). Trial code EudraCT 2011-002172-16.
Collapse
Affiliation(s)
- A Poveda
- Department of Gynecologic Oncology, Instituto Valenciano de Oncología, Valencia
| | - J M Del Campo
- Department of Medical Oncology, Hospital Vall d'Hebrón, Barcelona, Spain
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard and University Claude Bernard, GINECO Group, Lyon
| | - J Alexandre
- Department of Medical Oncology, Paris Descartes University, GH Cochin Hôtel Dieu, Paris
| | - M Provansal
- Department of Medical Oncology, Institut Paoli Calmettes Marseille, France
| | - E M Guerra Alía
- Department of Medical Oncology, Hospital Ramón y Cajal, Madrid
| | - A Casado
- Department of Medical Oncology, Hospital Clínico Universitario San Carlos, Madrid
| | | | - C Fernández
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - I Rodriguez
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - A Soto
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - C Kahatt
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | | | - C M Galmarini
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | | | - P Bohan
- Clinical R&D, Pharma Mar, S.A, Colmenar Viejo, Madrid, Spain
| | - D Berton-Rigaud
- Department of Oncology, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes-Saint Herblain, France
| |
Collapse
|
8
|
Affiliation(s)
- A Poveda
- Department of Gynecologic Oncology, Fundación Instituto Valenciano de Oncología. Valencia, Spain
| | - I Romero
- Department of Gynecologic Oncology, Fundación Instituto Valenciano de Oncología. Valencia, Spain
| |
Collapse
|
9
|
Casali P, Le Cesne A, Poveda A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Gelderblom H, Penel N, Kopp HG, Goldstein D, Broto JM, Gronchi A, Wardelmann E, Marreaud S, Zalcberg J, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Pujade-Lauraine E, Ledermann J, Penson R, Oza A, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.505] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
11
|
McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore K, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol 2017; 28:702-710. [DOI: 10.1093/annonc/mdx010] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Indexed: 12/13/2022] Open
|
12
|
Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, Estival A, Vicente D, Rubió J, Martin-Broto J. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016). Clin Transl Oncol 2016; 18:1221-1228. [PMID: 27896638 PMCID: PMC5138245 DOI: 10.1007/s12094-016-1579-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Accepted: 11/12/2016] [Indexed: 12/17/2022]
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
Collapse
Affiliation(s)
- A Poveda
- Department of Medical Oncology, Instituto Valenciano de Oncología, IVO, Valencia, Spain
| | - V Martinez
- Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
| | - C Serrano
- Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - I Sevilla
- Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain
| | - M J Lecumberri
- Department of Medical Oncology, Complejo Hospitalario de Navarra, Navarre, Spain
| | - R D de Beveridge
- Musculoskeletal and Gastric Tumor Unit, Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - A Estival
- Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Badalona, Hospital Germans Trias i Pujol, Badalona, Spain
| | - D Vicente
- Department of Medical Oncology, Hospital Universitario Virgen Macarena, Badalona, Spain
| | - J Rubió
- Department of Medical Oncology, Instituto Catalán de Oncología, ICO-Girona, Hospital Josep Trueta, Girona, Spain
| | - J Martin-Broto
- Department of Medical Oncology and Insituto de Biomedicina, IBIS, Hospital Universitario Virgen del Rocio, Av. Manuel Siurot, s/n, 41013, Sevilla, Spain.
| |
Collapse
|
13
|
Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch A, Dei Tos AP, Collini P, Jurado JC, De Paoli A, Donati DM, Poveda A, Quagliuolo V, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol 2016; 27:2283-2288. [PMID: 27733375 DOI: 10.1093/annonc/mdw430] [Citation(s) in RCA: 79] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2016] [Revised: 08/23/2016] [Accepted: 09/05/2016] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND To report on long-term results of a phase 3 trial comparing three versus five cycles of adjuvant chemotherapy (CT) with full-dose epirubicin+ifosfamide in high-risk soft tissue sarcomas (STS). METHODS Patients (pts) were randomized to receive three preoperative cycles of epirubicin 120 mg/m2 and ifosfamide 9 g/m2 (Arm A) or to receive the same three preoperative cycles plus two postoperative cycles (Arm B). Radiotherapy could be either delivered in the preoperative or in the postoperative setting. Non-inferiority of the primary end point, OS, was assessed by the confidence interval of the hazard ratio (HR; Arm A/Arm B) derived from Cox model. RESULTS Between January 2002 and April 2007, 164 pts were assigned to arm A and 164 to arm B. At a median follow-up (FU) of 117 months (IQ range 103-135 months), 123 deaths were recorded: 58 in Arm A and 65 in Arm B. Ten-year OS was 61% for the entire group of patients: 64% in Arm A and 59% in Arm B. The intention-to-treat analysis confirmed that three cycles were not inferior to five cycles (one-sided 95% upper confidence limit was 1.24). A per protocol analysis was consistent with these results. Pts with leiomyosarcoma and undifferentiated pleomorphic sarcoma (UPS) had the lowest, and the highest response rates, respectively. Consistently, Leiomyosarcoma and UPS had the worse and the best prognosis, respectively. CONCLUSIONS At a longer FU, the non-inferiority of three cycles of a full-dose conventional CT in comparison to five is confirmed. Response to therapy is also confirmed to be associated with better survival. This regimen is currently tested within an ongoing international trial against three cycles of a neoadjuvant histology-tailored CT (ClinicalTrials.gov Identifier: NCT01710176).
Collapse
Affiliation(s)
| | | | - P Verderio
- Department of Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - S Ferrari
- Department of Cancer Medicine, Istituto Ortopedico Rizzoli, Bologna, Italy
| | - J Martin Broto
- Department of Cancer Medicine, Hospital Universitario Virgen del Rocio, Sevilla
| | - A Lopez-Pousa
- Department of Cancer Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - A Llombart-Bosch
- Department of Pathology, Medical School University of Valencia, Valencia, Spain
| | - A P Dei Tos
- Department of Pathology, Treviso General Hospital, Treviso
| | - P Collini
- Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - J Cruz Jurado
- Department of Cancer Medicine, University of Canarias Hospital, La Laguna, Spain
| | - A De Paoli
- Department of Radiation Oncology, Centro di Riferimento Oncologico, Aviano
| | - D M Donati
- Department of Orthopedic Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy
| | - A Poveda
- Department of Cancer Medicine, Valencian Oncologic Institute, Valencia, Spain
| | - V Quagliuolo
- Department of Surgery, Humanitas Cancer Center, Rozzano
| | - A Comandone
- Department of Cancer Medicine, Presidio Sanitario Gradenigo, Torino
| | - G Grignani
- Department of Cancer Medicine, IRCC Fondazione Piemontese per la Ricerca sul Cancro, Candiolo
| | - C Morosi
- Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - A Messina
- Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - R De Sanctis
- Department of Cancer Medicine, Humanitas Cancer Center, Rozzano
| | - S Bottelli
- Department of Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | | | | | - Piero Picci
- Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy
| |
Collapse
|
14
|
Batista M, Romero I, Molina J, Brot L, Costa A, López R, Mallol P, Palacios J, Illueca C, Mendes C, Machado G, Santiago A, Rego E, López J, Poveda A. Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Ayala-Ramírez P, Buitrago T, Poveda A, Rodríguez JL, Olaya-C M, García-Robles R. Increased tissue factor and thrombomodulin expression and histopathological changes in placentas of pregnancies with preeclampsia. J Neonatal Perinatal Med 2016; 9:31-39. [PMID: 27002259 DOI: 10.3233/npm-16915034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Preeclampsia has a global frequency of 2-8% and a frequency of 10% in developing countries. In Colombia, preeclampsia causes 42% of maternal mortality. Alterations in placental homeostasis have been proposed to be involved in its pathophysiology. The aim of this study was to compare mRNA and protein levels of tissue factor (F3) and thrombomodulin (THBD) and the histopathological findings of placentas. MATERIALS AND METHODS We studied 16 placentas from patients with preeclampsia and 19 term placentas with uncomplicated pregnancy. An expert pathologist, who was masked to the group assignment, conducted an evaluation to determine specific histological changes. Assessments of mRNA and protein levels of F3 and THBD were performed using real-time PCR and ELISA, respectively. RESULTS Cases and controls differed in the frequency of decidual arteriopathy (p = 0.027), acute infarction (p = 0.001) and hyperplasia of the syncytiotrophoblast (p = 0.0017). Cases had increased levels of F3 mRNA (p = 0.0124) and protein (p < 0.0001) and THBD mRNA (p < 0.0001) and protein (p < 0.0001). CONCLUSION In placenta of patients with preeclampsia, we detected abnormal expression of F3 and THBD with increased protein and mRNA levels. The role of these molecules in the pathogenesis of this disease and in alterations of hemostatic and histopathological aspects of placentas need further studying.
Collapse
Affiliation(s)
- P Ayala-Ramírez
- Institute of Human Genetics, School of Medicine>, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - T Buitrago
- Institute of Nutrition, Genetics and Metabolism Research, Universidad El Bosque, Bogotá, Colombia
| | - A Poveda
- Institute of Human Genetics, School of Medicine>, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - J L Rodríguez
- Department of Pathology, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogotá, Colombia
| | - M Olaya-C
- Department of Pathology, Hospital Universitario San Ignacio-Pontificia Universidad Javeriana, Bogotá, Colombia
| | - R García-Robles
- Institute of Nutrition, Genetics and Metabolism Research, Universidad El Bosque, Bogotá, Colombia
| |
Collapse
|
16
|
Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life. Support Care Cancer 2015; 24:1241-9. [PMID: 26304156 DOI: 10.1007/s00520-015-2873-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Accepted: 07/27/2015] [Indexed: 11/12/2022]
Abstract
BACKGROUND A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response rate in the experimental arm compared to standard treatment, and less likelihood of normalized CA125 within the first 3 months. At 43 months follow-up, there were no significant group differences in progression-free survival. There were also significantly more side effects in the experimental arm. METHODS The current study examined quality of life (QoL) endpoints using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and the ovarian cancer module, QLQ-OV28, administered prior to randomization, at day 1 of treatment cycles 3, 5, and 7, at completion of the last cycle, and at 3 and 6 months following completion of chemotherapy. RESULTS Global QoL, physical symptoms, fatigue, and role, emotional, cognitive and social function (all from the EORTC QLQ-C30) significantly improved in both treatment arms, with no significant between-arm differences. Between-group differences in pain, insomnia, and peripheral neuropathy reported while on treatment did not differ at follow-up. Nausea and vomiting improved more with standard treatment both during and after treatment. Body image significantly differed between the groups only at cycle 5 (more deterioration in Arm 2) but group differences disappeared at follow-up. A stratified analysis of global QoL by debulking surgery status found no greater effect indicating that overall improvements in QoL were unrelated to surgical recovery. CONCLUSIONS There was no significant QoL advantage of cisplatin-topotecan. This finding, combined with no progression-free survival conferred by this combination, reaffirms carboplatin-paclitaxel as the standard of care for women with newly diagnosed ovarian cancer.
Collapse
Affiliation(s)
- Lori Brotto
- University of British Columbia, Vancouver, British Columbia, Canada.
| | - Michael Brundage
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Paul Hoskins
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Ignace Vergote
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Andres Cervantes
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Herraez A Casado
- University of British Columbia, Vancouver, British Columbia, Canada
| | - A Poveda
- University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Dongsheng Tu
- University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
17
|
Monk B, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A, Nieto A, Park Y, Cheng P, Li W, Favis R, Ricci D, Poveda A. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Ann Oncol 2015; 26:914-920. [DOI: 10.1093/annonc/mdv071] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 02/09/2015] [Indexed: 01/05/2023] Open
|
18
|
Endres H, Keller HJ, Lehmann R, Poveda A, Rupp HH, Sand HVD. Linear Chain Bis(α,β-dionedioximato)metal Compounds of the Nickel Triad: Solid State Design by Molecular Engineering. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znb-1977-0508] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Chemical and structural data of numerous bis(α,β-dionedioximato)metal(II) compounds are summarized. All of them crystallize in columns but principally two different kinds of molecular arrangements occur in the solids. In one phase the molecular planes are inclined to the direction of the linear metal chains with an angle different from 90°. This allows only indirect interactions between the metal ions via the ligand. (“M—L—M” stacking.) The other modification consists of molecules with their planes perpendicular to the M—M-chains. This form allows direct metal-metal contacts (“M—M” modification). Depending on a few molecular parameters a “M—L—M” or a “M—M” stacking is obtained upon crystallization. Since for those compounds which could be isolated in both modifications the M—L—M form has the higher density it is concluded that only stronger M—M interactions stabilize the less dense M—M forms.
A wide range of metal-metal separations with a lower limit of 3.15 Å in mixed valence systems are found in different “M—M” compounds. In any case the intrachain metal-metal distances are reduced considerably upon oxidation of the bivalent complex molecules. The influence of “electronic” and “sterical” parameters of the complex molecules on the intermolecular metal interactions and on the type of columns in the solid state is discussed.
Collapse
Affiliation(s)
- H. Endres
- Anorganisch-Chemisches Institut der Universität Heidelberg
| | - H. J. Keller
- Anorganisch-Chemisches Institut der Universität Heidelberg
| | - R. Lehmann
- Anorganisch-Chemisches Institut der Universität Heidelberg
| | - A. Poveda
- Anorganisch-Chemisches Institut der Universität Heidelberg
| | - H. H. Rupp
- Anorganisch-Chemisches Institut der Universität Heidelberg
| | - H. Van De Sand
- Anorganisch-Chemisches Institut der Universität Heidelberg
| |
Collapse
|
19
|
Monk B, Ghatage P, Parekh T, Henitz E, Knoblauch R, Soto Matos-Pita A, Nieto A, Park Y, Ricci D, Poveda A. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: Exploratory analysis of phase III OVA-301 study. Gynecol Oncol 2014. [DOI: 10.1016/j.ygyno.2014.03.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Gimeno-Perez M, Santos-Moriano P, Fernandez-Arrojo L, Poveda A, Jimenez-Barbero J, Ballesteros A, Fernandez-Lobato M, Plou F. Regioselective synthesis of neo-erlose by the β-fructofuranosidase from Xanthophyllomyces dendrorhous. Process Biochem 2014. [DOI: 10.1016/j.procbio.2013.12.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
21
|
Poveda A, Jelenkovic A, Salces I, Ibañez M, Rebato E. Heritability variations of body linearity and obesity indicators during growth. HOMO 2012; 63:301-10. [DOI: 10.1016/j.jchb.2012.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2010] [Accepted: 03/12/2012] [Indexed: 10/28/2022]
|
22
|
Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 2011; 55:680-687. [PMID: 21150863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM The aim of this study was to evaluate the utility of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) in monitoring response in refractory GIST. METHODS This multicenter study prospectively evaluated 21 patients with locally advanced and/or metastatic GIST refractory to with high-dose imatinib (800 mg/day) treated with doxorubicin 15-20 mg/m2/weekly for 4 cycles, followed by imatinib maintenance (400 mg/day). CT and FDG-PET were performed at baseline and after completion of therapy. RESULTS Mean baseline tumor size on CT was 5.9 cm. Median progression-free survival (PFS) was 219 days (range 62-1108). Three out of 21 patients (14%) had partial responses (PR) under RECIST criteria, 12 patients (57%) remained stable (SD) and 6 showed progression (PD) of the disease during treatment (29%). Six patients had PR by FDG-PET, 15 showed SD (n=9) or PD (n=6) based on EORTC criteria. Patients with a PFS <6 mo showed a significantly higher ∑SUVmax at baseline (26.04±13.4) than those with PFS≥6 mo (9.82±5.0) (P<0.05). A correlation was found between PET response and PFS: PR 14±6.1 mo, SD 5.5±0.8 mo and PD 3.5±4.1 mo (P<0.05). A residual SUVmax <5 after treatment correlated with improved PFS (314±315 days vs 131±91 days) (P<0.01). Survival curves showed a significant association between PET response and PFS (P<0.05). Patients with wild-type genotype KIT (KIT-WT) showed a significantly lower baseline SUVmax (5.36±1.4) than non-WT KIT (8.40±3.6) (P<0.05). CONCLUSION FDG-PET is useful in assessing response of GIST refractory to imatinib and correlates with the presence of KIT-WT. Baseline ∑SUVmax can predict response to treatment in this series.
Collapse
Affiliation(s)
- D Fuster
- Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Poveda A, López-Pousa A, Martín J, Del Muro JG, Bernabé R, Casado A, Balañá C, Sanmartín O, Menéndez MD, Escudero P, Cruz J, Belyakova E, Menéndez D, Buesa JM. Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 2011; 9:127-32. [PMID: 18521419 PMCID: PMC2395634 DOI: 10.1080/13577140500287024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2005] [Revised: 07/05/2005] [Accepted: 07/22/2005] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR. PATIENTS AND METHODS Patients with measurable and progressive STS received PLD at 35 mg/(2) every 3 weeks. Quality of life before and during treatment was assessed with EORTC QLQ-C30. RESULTS Twenty-eight patients, 22 DXR-pretreated, were given 140 cycles (median 3, range 1-18). Activity in 27 patients (5 GIST): one complete and one partial remission (both non-GIST and without prior DXR), 12 stabilizations and 13 progressions (response rate 7.4%, 95% CI: 0-17%). Grade 3 toxicity: palmar-plantar erythrodysesthesia (19% of patients), stomatitis (4%) or cutaneous (4%). Neutropenia grade>/=3 was detected in 16% of patients. Median relative dose intensity was 95%. Progression-free rate at 3 and 6 months was, respectively, 48 and 22%, median progression-free survival 5.8 months and median overall survival 8.7 months. QLQ-C30 at baseline and at weeks 6-11 in 23 and 13 patients, respectively, showed good reliability and validity. Quality of life did not seem to worsen during therapy. CONCLUSIONS PLD did not induce objective remissions in 22 STS patients pretreated with DXR, but progression-free rate figures support the use of this agent in patients who have not progressed under a DXR-containing regimen. The toxicity observed was comparable to that of other PLD schedules.
Collapse
Affiliation(s)
- A Poveda
- Instituto Valenciano de Oncología Valencia Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Oza AM, Poveda A, Clamp AR, Pignata S, Scambia G, Del Campo JM, McCormack M, Sevcik L, Schwartz BM, Guan S, Lee R, Cheng JD, Haluska FG. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5009] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Poveda A, Monk BJ, Kaye SB, Vermorken JB, Vergote IB, Runnebaum IB, Pujade-Lauraine E, Parekh TV, Nieto A, Gomez J, Park YC, Colombo N. Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Martin Broto J, Garcia del Muro X, Gutierrez A, Martinez-Trufero J, Serrano T, Rubió J, Lainez N, Sevilla I, Cruz J, Ramos R, Ortega L, Poveda A, Ramirez M, Cubedo R, Lopez-Guerrero J. KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Rubió J, Martinez-Trufero J, Lopez-Pousa A, Garcia del Muro X, Fra J, Redondo A, Lainez N, Poveda A, Casado A, Valverde CM, De Juan A, Sevilla I, Andres R, Cruz J, Safont MJ, Martin Broto J, Garcia-Albeniz X, Maurel J. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia F, Pujade-Lourraine E, Zintl P, Parekh TV, Poveda A. Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali P, Cesne AL, Jones R, Blay JY, Poveda A, Maki R, Nieto A, Tercero J, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur J Cancer 2011; 47:1006-12. [DOI: 10.1016/j.ejca.2011.01.016] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2010] [Revised: 01/06/2011] [Accepted: 01/20/2011] [Indexed: 10/18/2022]
|
30
|
Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, Lebedinsky C, Parekh T, Santabárbara P, Park YC, Nieto A, Poveda A. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2011; 22:49-58. [PMID: 20643863 PMCID: PMC3003617 DOI: 10.1093/annonc/mdq353] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Revised: 05/10/2010] [Accepted: 05/12/2010] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6-12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. PATIENTS AND METHODS a detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. RESULTS similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). CONCLUSION the superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these exploratory analyses support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
Collapse
Affiliation(s)
- S B Kaye
- Section of Medicine, Institute of Cancer Research, The Royal Marsden Hospital, Sutton, Surrey, UK.
| | - N Colombo
- Medical Gynecologic Oncology Unit, European Institute of Oncology, Milan, Italy
| | - B J Monk
- Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA
| | - S Tjulandin
- Department of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow, Russia
| | - B Kong
- Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, Shandong, China
| | - M Roy
- Department of Gynecologic Oncology, University Hospital Center, Quebec, Canada
| | - S Chan
- Department of Clinical Oncology, Nottingham University Hospital, Nottingham, UK
| | | | - H Hagberg
- Department of Oncology, Akademiska Sjukhuset, Uppsala, Sweden
| | - I Vergote
- Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital, Leuven, Belgium
| | - C Lebedinsky
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - T Parekh
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA
| | - P Santabárbara
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - Y C Park
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA
| | - A Nieto
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - A Poveda
- Department of Medical Oncology, Valencian Institute of Oncology, Valencia, Spain
| |
Collapse
|
31
|
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011; 22:39-48. [PMID: 20643862 PMCID: PMC3003616 DOI: 10.1093/annonc/mdq352] [Citation(s) in RCA: 111] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Revised: 05/25/2010] [Accepted: 05/25/2010] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. PATIENTS AND METHODS within OVA-301, we therefore now report on the outcomes for the 214 cases in this subgroup. RESULTS Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) = 0.65, 95% confidence interval (CI), 0.45-0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5 months], and a significant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43-0.82; P = 0.0015; median survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population. Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the trabectedin/PLD arm survived significantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3 versus 9.8 months). CONCLUSION This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6-12 months).
Collapse
Affiliation(s)
- A Poveda
- Area of Gynecologic Oncology, Valencian Institute of Oncology, Valencia, Spain.
| | - I Vergote
- Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospital, Leuven, Belgium
| | - S Tjulandin
- Department of Clinical Pharmacology and Chemotherapy, Russian Cancer Research Center, Moscow, Russia
| | - B Kong
- Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji'nan, Shandong, China
| | - M Roy
- Department of Gynecologic Oncology, University Hospital Center, Quebec, Canada
| | - S Chan
- Department of Clinical Oncology, Nottingham University Hospital, Nottingham, UK
| | | | - H Hagberg
- Department of Oncology, Akademiska Sjukhuset, Uppsala, Sweden
| | - S B Kaye
- Department of Cancer Medicine, The Royal Mardsen Hospital, Sutton, Surrey, UK
| | - N Colombo
- Medical Gynecologic Oncology Unit, European Institute of Oncology, Milan, Italy
| | - C Lebedinsky
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - T Parekh
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ
| | - J Gómez
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - Y C Park
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ
| | - V Alfaro
- Clinical R&D and Medical Affairs Department, Pharma Mar, Madrid, Spain
| | - B J Monk
- Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, USA
| |
Collapse
|
32
|
Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel. J Natl Cancer Inst 2010; 102:1547-1556. [DOI: 10.1093/jnci/djq362] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
33
|
Poveda A, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Lebedinsky C, Parekh TV, Monk BJ. Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Pecorelli S, Ray-Coquard I, Tredan O, Colombo N, Parma G, Tisi G, Katsaròs D, Lhommé C, Lissoni AA, Vermorken JB, du Bois A, Poveda A, Frigerio L, Barbieri P, Carminati P, Brienza S, Guastalla JP. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol 2010; 21:759-765. [PMID: 19906760 PMCID: PMC2844948 DOI: 10.1093/annonc/mdp514] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2009] [Revised: 10/01/2009] [Accepted: 10/06/2009] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND A prospective phase II study was conducted to evaluate the efficacy and toxicity of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. PATIENTS AND METHODS Patients had a maximum of three prior chemotherapy lines with no more than two prior platinum-containing regimens and a progression-free interval after the last dose of platinum <12 months. A total dose of 4 mg/m(2)/cycle (0.8 mg/m(2)/day from day 1 to day 5) was administered, repeated every 28 days. RESULTS From June 2005 to December 2005, 69 assessable patients were enrolled. The best overall response to study treatment by combined CA-125 and RECIST criteria was partial response in 17 patients (24.6%) and disease stabilization in 22 patients (31.9%). The median time to progression and overall survival were 3.8 and 16.2 months, respectively. A total of 312 cycles were administered. Neutropenia grade 4 and thrombocytopenia grade 4 occurred in 17.4% and 7.2% of patients, respectively. Diarrhea grade 4 was never observed. Asthenia and fatigue were reported by 36.2% and 18.8% of patients, but were all grade 2 or less. CONCLUSION Gimatecan is a new active agent in previously treated ovarian cancer with myelosuppression as main toxicity.
Collapse
Affiliation(s)
- S Pecorelli
- Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - O Tredan
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - N Colombo
- Medical Gynecologic Oncology Unit, European Institute of Oncology, University of Milan Bicocca, Milan, Italy
| | - G Parma
- Medical Gynecologic Oncology Unit, European Institute of Oncology, University of Milan Bicocca, Milan, Italy
| | - G Tisi
- Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
| | - D Katsaròs
- Gynecologic Oncology Unit, University of Turin, Turin, Italy
| | - C Lhommé
- Department of Medical Gynaecology-Oncology, Institut Gustave Roussy, Villejuif, France
| | - A A Lissoni
- Gynecologic Oncology Unit, San Gerardo Hospital, University of Milan Bicocca, Monza, Italy
| | - J B Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
| | - A du Bois
- Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik (HSK), Wiesbaden, Germany
| | - A Poveda
- Onco Gynecological Area, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| | - L Frigerio
- Department of Obstetrics and Gynecology, Ospedali Riuniti, Bergamo, Italy
| | - P Barbieri
- sigma-tau Research Switzerland S.A., Mendrisio, Switzerland.
| | - P Carminati
- sigma-tau Industrie Farmaceutiche Riunite S.p.A., Pomezia (Roma), Italy
| | - S Brienza
- Debioclinic S.A., Charenton le Pont, France
| | - J P Guastalla
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| |
Collapse
|
35
|
Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010; 21:1552-1557. [PMID: 20231303 DOI: 10.1093/annonc/mdq047] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND To assess whether deletions involving codons 557 and/or 558 (critical deletions) of exon 11 of KIT are relevant in the prognosis of relapse-free survival (RFS) in gastrointestinal stromal tumor (GIST) patients with a long follow-up. PATIENTS AND METHODS A univariate and multivariate analysis for RFS were carried out on 162 localized GIST patients over the entire follow-up period and over the intervals 0-4 years and >4 years. Factors assessed among others were Fletcher/National Institutes of Health and Miettinen-Lasota/Armed Forces Institute of Pathology (M-L/AFIP) risk categories, critical deletions and non-deletion-type mutation (NDTM) within exon 11 of KIT. RESULTS Multivariate analyses revealed that M-L/AFIP [relative risk (RR) 11.45, confidence interval (CI) 4.40-29.76, for the high-risk subgroup and RR 5.97, CI 2.09-17.06, for the intermediate subgroup] and critical deletions (RR 3.05, CI 1.59-5.85) were independent prognostic factors for RFS for the first 4 years and for the entire follow-up period. Beyond 4 years, the high-risk M-L/AFIP subgroup (RR 8.12, CI 1.48-44.4) and NDTM (RR 6.42, CI 1.17-35.12) were independent prognostic factors for RFS. The median follow-up was 84 months. CONCLUSION Critical deletions represent a time-dependent prognostic factor limited to the first 4 years after surgery, which could help identify a subset with higher and earlier risk for relapse in GIST patients.
Collapse
Affiliation(s)
- J Martin-Broto
- Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca.
| | - A Gutierrez
- Departments of Oncology and Hematology, Medical and Translational Hemato-Oncology Group, Hospital Universitario Son Dureta, Palma de Mallorca
| | | | - J A Lopez-Guerrero
- Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia
| | | | - L M de Sande
- Department of Oncology, Complejo Hospitalario de León, Leon
| | - N Lainez
- Department of Oncology, Hospital Virgen del Camino, Pamplona
| | - J Maurel
- Department of Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas, Barcelona
| | - A De Juan
- Oncology Department, Hospital de Valdecilla, Santander
| | - F Losa
- Department of Oncology, Hospital General, Hospitalet de Llobregat
| | - R Andres
- Department of Oncology, Hospital Clínico Lozano Blesa, Zaragoza
| | - A Casado
- Department of Oncology, Hospital Universitario San Carlos, Madrid
| | - P G Tejido
- Department of Oncology, Hospital San Pedro, Logroño
| | - R Blanco
- Department of Oncology, Hospital Mutua de Terrassa, Terrassa
| | - J Carles
- Department of Oncology, Hospital del Mar, Barcelona
| | - J Bellmunt
- Department of Oncology, Hospital Vall d'Hebron, Barcelona
| | | | - R Ramos
- Department of Pathology, Hospital Universitario Son Dureta, Palma de Mallorca
| | - J Martinez-Serra
- Laboratory of Molecular Biology, Hospital Universitario Son Dureta, Palma de Mallorca
| | | | - A Poveda
- Department of Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
36
|
Poveda A, Kaye S, Herzog T, Ghatage P, Meerpohl H, Ngan H, Emerich J, Tercero J, Ricci D, Monk B. 8005 Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs Trabectedin (T) + PLD in the ET743-OVA-301 clinical trial. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71527-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
37
|
Vergote I, Vermorken J, Pujade-Lauraine E, Monk B, Lisyanskaya A, Rolski J, Vasanthan S, Santabárbara P, Bayever E, Poveda A. 8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71550-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
38
|
Bidzinski M, Poveda A, Vermorken J, Kaye S, Makhson A, Jagiello-Gruszfeld A, Poole C, Gomez J, Parekh T, Monk B. 8064 Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71586-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
39
|
Krasner CN, Poveda A, Herzog T, Vermorken J, Monk B, Zintl P, Li J, Su Y, Dhawan R, Kaye S. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5526 Background: In an open-label, multicenter, randomized phase III study comparing the combination of trabectedin and PLD to PLD alone in patients with relapsed ovarian cancer, the combination demonstrated significantly improved progression free survival and response rates, manageable non-cumulative toxicity, and fewer PLD-associated adverse events. We studied the impact of the combination of trabectedin with PLD on the quality of life (QoL)/patient-reported outcomes (PRO) evaluated as part of the trial. Methods: QoL/PRO questionnaires, EORTC-QLQ C30, OV28, and EQ-5D were completed by patients at screening and on Day 1 of every other treatment cycle starting with Cycle 1, and at the end-of-treatment visit. Global health status/QoL, fatigue, rain subscales from QLQ C30, and abdominal pain/GI symptoms scale from OV28 were chosen a priori for primary analyses. Other scales of the three questionnaires were analyzed on a supportive basis. Results: A total of 672 patients were randomized. 663 (98%) completed at least the baseline questionnaires. Median cycles of treatment was 6 (131 days) for the combination arm and 5 (143 days) for the monotherapy arm. Mixed effects models (using a covariance structure of AR[1]) predicting the score at baseline and follow-up scores as a function of treatment, days after baseline, and interaction between treatment and days after baseline showed no significant differences between the treatment arms for any of the prespecified scales. Similar analyses of other scales, including EQ-5D Health Index scores and Health State on the Visual Analog Scale, support the findings. Conclusions: The addition of trabectedin to PLD results in superior efficacy in patients with relapsed ovarian cancer, with no added decrement to overall health status as assessed by PRO. [Table: see text]
Collapse
Affiliation(s)
- C. N. Krasner
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - A. Poveda
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - T. Herzog
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - J. Vermorken
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - B. Monk
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - P. Zintl
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - J. Li
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - Y. Su
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - R. Dhawan
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| | - S. Kaye
- Massachusetts General Hospital, Boston, MA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar, S.A., Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
| |
Collapse
|
40
|
Matias-guiu X, Dolcet X, Llobet D, Poveda A, Pallares J, Eritia N, Yeramian A, Sorolla A, Ortega E, Llombart-Cussac A. Targeting the extrinsic apoptotic pathway in endometrial carcinoma cell lines and tumor cell explants. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16555 Background: Endometrial carcinoma (EC) frequently shows deregulation of the extrinsic apoptotic pathway. One of the critical regulators of apoptosis resistance in EC is FLIP, under the control of NFkB and a cellular complex composed of CK2, KSR1, and BRAF. Methods: Four different EC cell lines, which are known to exhibit resistance to TRAIL/FAS-induced apoptosis (Ishikawa, KLE, HEC1A, and RL-95) were exposed to various pharmacologic substances that target proteins involved in the regulation of the extrinsic apoptotic pathway and receptor tyrosine kinases including bortezomib, sorafenib, sunitinib, DRB, apigenin, MG-132, epoxomicin, and ALLN. Moreover, EC cell lines were subjected to down-regulation of several of these genes (FLIP, CK2, KSR1, and BRAF) by shRNA. Cell viability and apoptotic morphology was determined. Results were validated in tumor cell explants. Results: Bortezomib induced cell death on EC cells and primary explants to a 70% extent. However, 100% of treated explants and cell lines activated NF-kB instead of blocking its transcriptional potential. Combination of sunitinib plus bortezomib induced 75% fold reduction in NFkB activity and induced a 5% of synergistic increse of apoptotic cell death in Ishikawa cells. Treatment of the four cell lines with TRAIL failed to induce cell death. However, FLIP knock-down sensitized the cells to TRAIL-induced apoptosis (80%). Moreover, down-regulation of CK2, KSR1, and BRAF by pharmacological inhibition, or shRNA, reduced FLIP cellular levels, and induced TRAIL-dependent apoptosis in 70%-100% of EC cell lines tested. Sorafenib induced a dose-dependent cell death in all four cell lines, to a 70%-100% extent at 48 hours. Conclusions: In vitro pharmacologic targeting of the apoptotic pathway effectively induces cell death in EC cell lines. These findings justify clinical trials with these agents in EC. [Table: see text]
Collapse
Affiliation(s)
- X. Matias-guiu
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - X. Dolcet
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - D. Llobet
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - A. Poveda
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - J. Pallares
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - N. Eritia
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - A. Yeramian
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - A. Sorolla
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - E. Ortega
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| | - A. Llombart-Cussac
- Hospital Universitario Arnau Vilanova, IRB_Lleida, Lleida, Spain; Fundación Instituto Valenciano Oncologia, Valencia, Spain
| |
Collapse
|
41
|
Poveda A, Kaye SB, McCormack RT, Wang S, Ricci D, Broderick E, Parekh T, Lebedinsky C, Tecero JC, Monk BJ. Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5551 Background: Circulating tumor cells (CTC) have demonstrated predictive and prognostic value among patients with metastatic breast, colorectal, and prostate cancer. In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin (T) vs PLD for relapsed ovarian cancer, we assessed the affect of CTCs on progression free survival, (PFS) and overall survival (OS). Methods: CTCs were isolated from peripheral blood (10 mLs) using the CellSearch system and reagents (Veridex). A CTC is defined as EpCAM+, cytokeratin+, CD45-, and is positive for the nuclear stain DAPI. The normal reference range for CellSearch is < 2 CTC/7.5 mLs of blood. Hazard ratios adjusted for known prognostic factors were estimated by Cox regression. Results: 216 subjects had baseline CTC measurements of which 111 (51.4%) were randomized to the PLD+T arm; 143/216 patients (66.2%) were platinum sensitive. Thirty-one/216 patients (14.4%) had 2 or more CTCs detected prior to the start of therapy (range 2–566). Univariate Cox regression analyses indicated that patient's > 2 CTCs prior to therapy have 1.89 (p = 0.003) and 2.06 (p = 0.003) fold higher risk for progression and death respectively. Multivariate analyses that include baseline CTC, baseline CA125, platinum sensitivity status, largest diameter lesion, number of tumor lesions, ECOG PS, age, tumor histology, tumor grade and prior taxane show that patients with elevated baseline CTC have 1.58 (p = 0.058) and 1.54 (p = 0.096) fold higher risk for progression and death respectively. Conclusions: Results from this study indicate that although CTC detection in blood from relapsed recurrent ovarian cancer patients is relatively low, elevated numbers of CTCs imparts an unfavorable prognosis for patients. Multivariate analysis indicates that CTCs have prognostic value that is independent of established factors and thus provides a clinically useful tool for assessing prognosis in this difficult to treat patient population. [Table: see text]
Collapse
Affiliation(s)
- A. Poveda
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - S. B. Kaye
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - R. T. McCormack
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - S. Wang
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - D. Ricci
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - E. Broderick
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - T. Parekh
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - C. Lebedinsky
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - J. C. Tecero
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| | - B. J. Monk
- Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Reseach & Development, Raritan, NJ; PharmaMar, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
| |
Collapse
|
42
|
Fuster D, Sierra A, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Garcia Del Muro X, Maurel J. Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10553 Background: Small changes in tumor size or density on computed tomography (CT) are sensitive and specific methods to assess response of GISTs and correlates well with positron emission tomography with 18F-Fluorodeoxyglucose (FDG-PET) in untreated GIST patients (pts). Despite of it, there is inconsistent prospective data in imatinib (IM) refractory disease. Methods: This multicenter phase I-II study prospectively evaluated 26 pts with metastatic high-dose IM refractory GISTs treated with doxorubicin 15 - 20 mg/m2/weekly per 4 cycles, followed by IM maintanance (400mg p.o.qd). CT and FDG-PET were performed at baseline and after 2 months of therapy. Response rate was assessed by RECIST criteria by Principal Investigator (PI). CT and FDG-PET (EORTC criteria) were reviewed by two experts in abdominal CT (AR) and one expert on Nuclear Medicine in one Institution. Results: Tumor density measurements were not assessed on CT because some studies were not available in DICOM format and different tube currents were used. There were significant lower number of lesions identified by PI (n=73; median 2, range 1–6) than AR (n=122; median 5, range 1–10). Twenty-eight out of 122 lesions identified by CT did not demonstrate significant uptake in FDG-PET at baseline (upon 800mg/day of IM treatment) on FDG-PET. Mean baseline tumor size on CT was 5.9cm (ranging from 0.9 to 28cm), and mean baseline SUVmax on FDG-PET was 7.2 (ranging from 1.9 to 26.4). Nine patients responded on FDG-PET compared with 2 pts and 5 pts with RECIST or modified RECIST criteria (decrease in tumor size more than 10%), respectively. The sensitivity for RECIST or modified RECIST in identifying PET responders was 22% and 55%, showing a 100% of specificity by both methods. Good responders on FDG-PET at 2 months had significantly longer progression free survival (264 days) than non-responders (64 days) (P=0.01). Conclusions: FDG-PET is sensitive and specific to assess response of GISTs pts refractory to high-dose IM. If the prognostic value of FDG-PET can be confirmed should be employed in future studies of pts with refractory GIST. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Fuster
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - A. Sierra
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - J. R. Ayuso
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - A. Poveda
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - R. Cubedo
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - A. Casado
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - J. Martínez-Trufero
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - A. López-Pousa
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - X. Garcia Del Muro
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| | - J. Maurel
- Hospital Clínic, Barcelona, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital Puerta de Hierro, Madrid, Spain; Hospital Clínico de Madrid, Madrid, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Sant Pau, Barcelona, Spain; Institut Català d'Oncologia, Barcelona, Spain
| |
Collapse
|
43
|
Poveda A, Gonzalez-Martin A. Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update. Ann Oncol 2008; 19 Suppl 7:vii70-6. [PMID: 18790983 DOI: 10.1093/annonc/mdn465] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- A Poveda
- Instituto Valenciano de Oncología, Department of Medical Oncology, Valencia, Spain
| | | |
Collapse
|
44
|
Reed N, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen J, Coens C, Teodorovic I, Vergote I, Vermorken J. Corrigendum to “Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)” [European Journal of Cancer, 44 (2008) 808–818]. Eur J Cancer 2008. [DOI: 10.1016/j.ejca.2008.01.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
45
|
Maurel J, Lopez-Pousa A, de las Peñas R, Fra J, Cruz J, Martin J, Casado A, Martinez-Trufero J, Poveda A, Garcia del Muro X. Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Poveda A, Maurel J, Cubedo R, Casado A, Ayuso J, Fuster D, Martinez-Trufero J, Lopez-Pousa A, Martin J, Garcia del Muro X. Phase I-II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: A GEIS Study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10520] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Martin J, Gutierrez A, Garcia del Muro J, Maurel J, Gonzalez de Sande LM, Martinez J, De Juan A, Lainez N, Losa F, Poveda A. Time dependence of critical deletions as prognostic factor for relapse-free survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Rubio M, Santaballa A, Garcia Y, Gonzalez A, Bover I, Calvo E, Contreras JA, del Campo J, De Juan A, Poveda A. Phase II study of weekly topotecan in recurrent or metastatic cervical cancer: a GEICO study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44:808-18. [PMID: 18378136 DOI: 10.1016/j.ejca.2008.01.019] [Citation(s) in RCA: 336] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2007] [Accepted: 01/07/2008] [Indexed: 11/30/2022]
Abstract
The management of uterine sarcomas continues to present many difficulties. Primary surgery is the optimal treatment but the role of post-operative radiation remains uncertain. In the mid-1980s, the European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study proposed a trial to evaluate adjuvant radiotherapy, as previous non-randomised studies had suggested a survival advantage and improved local control when post-operative radiation was administered. The study opened in 1987 taking 13 years to accrue 224 patients. All uterine sarcoma subtypes were permitted. Patients were required to have undergone as a minimum, TAH and BSO and wahsings (166 patients) but nodal sampling was optional. There were 103 leiomyosarcomas (LMS), 91 carcinosarcomas (CS) and 28 endometrial stromal sarcomas (ESS). Patients were randomised to either observation or pelvic radiation, 51 Gy in 28 fractions over 5 weeks. Hundred and twelve were recruited to each arm. The initial analysis has shown a reduction in local relapse (14 versus 24, p=0.004) but no effect on either OS or PFS. No unexpected toxicity was seen in the radiation arm. No difference in either overall or disease-free survival was demonstrated but there is an increased local control for the CS patients receiving radiation but without any benefit for LMS. Prognostic factor analysis shows that stage, age and histological subtype were important predictors of behaviour which may explain differences between CS and LMS. CS appears to show more kinship to poorly differentiated endometrial carcinomas in behaviour. LMS did not show the same benefit from radiation. These results will help shape future management and clinical trials in uterine sarcomas.
Collapse
Affiliation(s)
- N S Reed
- Beatson Oncology Centre, Gartnavel General Hospital, Glasgow G12 0YN, Scotland, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
TheInternational Symposium on Advanced Ovarian Cancer: Optimal Therapywas founded by Dr. Andrés Poveda and Prof. Jan B. Vermorken, and each edition has been directed by them. The 6th edition was held on March 2, 2007. This symposium is organized every other year by GEICO (Grupo Español de Investigación de Cáncer de Ovario/Spanish Ovarian Cancer Research Group), under the auspices of the Spanish Society of Medical Oncology (SEOM), the Gynecologic Cancer Intergroup (GCIG), and the European Society of Medical Oncology (ESMO) Educational Committee for its Medical Oncology Recertification Approval (ESMO/MORA) Program. One hundred and fifty people attended the symposium's 1st edition, held in 1996. Since then, the interest in this meeting has increased. Last year, almost three hundred people coming not only from Spain but also from Europe, North and Latin America, Asia, and Australia were present in the symposium. This is a great challenge for us. Some important international cooperative groups from Europe, America, and Australia collaborate with this symposium, such as GOG, NCIC, EORTC, AGO, Scottish Group, ICON, GINECO, NSGO, ANZGOG, and others.
Collapse
|